EC
MAZE

EntryPoint Capital’s Maze Therapeutics MAZE Stock Holding History

EntryPoint Capital’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Buy
+9,814
New +$257K 0.07% 564

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

EntryPoint Capital's MAZE Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 9,814 shares worth $293K. The stake represents 0.07% of the portfolio and ranks #564 among its holdings.

162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • EntryPoint Capital held 9,814 shares of Maze Therapeutics worth $293K as of Q2 2026.
  • Maze Therapeutics was a new EntryPoint Capital position in Q2 2026.
  • Maze Therapeutics made up 0.07% of EntryPoint Capital's portfolio in Q2 2026, its #564 holding.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.